姑息放疗联合阿帕替尼在Ⅳ期胰腺癌治疗中的应用  

Application of palliative radiotherapy combined with apatinib in the treatment of stage Ⅳ pancreatic cancer

作　　者：薛志东[1] 杨艳[1] XUE Zhi-dong;YANG Yan(Department of Oncology,Taizhou People's Hospital,Taizhou Jiangsu 225300,China)

机构地区：[1]江苏省泰州市人民医院肿瘤科,江苏泰州225300

出　　处：《临床和实验医学杂志》2020年第22期2410-2413,共4页Journal of Clinical and Experimental Medicine

基　　金：江苏省青年医学重点人才培养计划项目(编号:QNRC2016829)。

摘　　要：目的探讨姑息放疗联合阿帕替尼在Ⅳ期胰腺癌患者中的临床应用。方法前瞻性选取2015年5月至2019年5月于泰州市人民医院肿瘤科收治的60例Ⅳ期胰腺癌患者作为研究对象,按照随机数字表法将其分为观察组和对照组,每组各30例。对照组给予姑息放疗治疗,观察组给予姑息放疗联合阿帕替尼治疗。比较2组患者的临床疗效、镇痛效果、无进展生存率、不良反应。结果观察组患者临床总有效率为83.33%,显著高于对照组的33.33%,差异有统计学意义(P<0.05)。观察组1、3、6、9个月无进展生存率分别为40.00%、33.33%、26.66%、16.66%,明显高于对照组的16.66%、10.00%、3.33%、0,差异有统计学意义(P<0.05)。治疗后观察组镇痛有效率83.33%,明显优于对照组的60.00%,差异有统计学意义(P<0.05)。观察组患者不良反应总发生率为86.66%,明显高于对照组的46.66%,差异有统计学意义(P<0.05)。结论姑息放疗联合阿帕替尼治疗Ⅳ期胰腺癌患者有助于提高疗效,延长患者生命,改善临床症状,减轻患者痛苦。Objective To investigate the clinical application of palliative radiotherapy combined with apatinib in patients with stage Ⅳ pancreatic cancer.Methods Sixty patients with stage Ⅳ pancreatic cancer who were admitted to Department of Oncology,Taizhou People's Hospital from May 2015 to May 2019 were selected as the research subjects.They were divided into observation group and control group with random number table,30 cases in each group.The control group was given palliative radiotherapy,and the observation group was given palliative radiotherapy combined with apatinib.The treatment effect,progression-free survival rate,the clinical efficacy,analgesic effect,progression-free survival rate,and adverse reactions were compared between the two groups of patients.Results The total clinical effective rate of patients in the observation group was 83.33%,which was significantly higher than that in the control group(33.33%),the difference was statistically significant(P<0.05).The 1-month,3-month,6-month,and 9-month progression-free survival rates in the observation group were 40.00%,33.33%,26.66%,and 16.66%,which were significantly higher than those in the control group of 16.66%,10.00%,3.33%,and 0,the difference was statistically significant(P<0.05).After treatment,the analgesic effectiveness of the observation group was 83.33%,which was significantly better than that of the control group(60.00%),the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 86.66%,which was significantly higher than that in the control group(46.66%),the difference was statistically significant(P<0.05).Conclusion Palliative radiotherapy combined with apatinib in patients with stageⅣpancreatic cancer can help can help improve the curative effect,prolong the life of the patient,improve the clinical symptoms,and relieve the suffering of the patient.

关 键 词：Ⅳ期胰腺癌 姑息放疗 阿帕替尼 

分 类 号：R735.9[医药卫生—肿瘤]